Table 2 Clinical trials on blocking amino acid metabolic pathways in combination with traditional therapeutics

IDO1

Inhibiting trp-kyn metabolism pathway and enhance anti-tumor immunity

Epacadostat

Biological: CRS-207

Platinum-resistant Ovarian Cancer, Fallopian Cancer, Fallopian Cancer

NCT02575807

I/II

Terminated

Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401

Drug: Poly ICLC

Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma

NCT02166905

I/II

Completed

Drug: Itacitinib

Solid Tumors

NCT02559492

I

Terminated

Drug: Azacitidine

Drug: Pembrolizumab

Drug: INCB057643

Drug: INCB059872

Solid Tumors, Advanced Malignancies, Metastatic Cancer

NCT02959437

I/II

Terminated

Biological: SV-BR-1-GM

Biological: INCMGA00012

Drug: Low dose cyclophosphamide

Biological: Interferon Inoculation

Breast Cancer Female, Breast Neoplasm Female

NCT03328026

I/II

Recruiting

Drug: Nivolumab

Drug: platinum chemotherapeutic drug

Lung Cancer

NCT03348904

III

Terminated

Drug: Pembrolizumab

Drug: Placebo

Urothelial Cancer

NCT03361865

III

Completed

Drug: Pembrolizumab

Drug: chemotherapeutic drug

Solid Tumor

NCT03085914

I/II

Completed

Drug: Nivolumab

Drug: Ipilimumab

Drug: Lirilumab

Solid Tumor

NCT03347123

I/II

Terminated

Drug: Retifanlimab

Endometrial Cancer

NCT04463771

II

Recruiting

Drug: Pembrolizumab

Biological: CRS-207

Drug: CY

Biological: GVAX

Metastatic Pancreatic Adenocarcinoma

NCT03006302

II

Active, not recruiting

Drug: Ipilimumab

Melanoma

NCT01604889

I/II

Terminated

Drug: INCB001158

Drug: Pembrolizumab

Solid Tumors

NCT03361228

I/II

Terminated

Drug: Pembrolizumab

Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma

NCT03602586

II

Terminated

Sarcoma

NCT03414229

II

Active, not recruiting

Renal Cell Carcinoma (RCC)

NCT03260894

III

Active, not recruiting

Head and Neck Cancer

NCT03358472

III

Active, not recruiting

Urothelial Cancer

NCT03374488

III

Completed

BMS-986205

Biological: Relatlimab

Biological: Nivolumab

Advanced Cancer

NCT03459222

I/II

Recruiting

Biological: Nivolumab

Radiation: Radiation Therapy

Drug: Temozolomide

Glioblastoma

NCT04047706

I

Recruiting

Drug: Nivolumab

Endometrial Adenocarcinoma, Endometrial Carcinosarcoma

NCT04106414

II

Active, not recruiting

Hepatocellular Carcinoma

NCT03695250

I/II

Active, not recruiting

Indoximod

Radiation: Partial Radiation

Radiation: Full-dose Radiation

Drug: Temozolomide

Drug: Cyclophosphamide

Drug: Etoposide

Drug: Lomustine

Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma

NCT04049669

II

Recruiting

Drug: Ipilimumab

Drug: Nivolumab

Drug: Pembrolizumab

Melanoma

NCT02073123

I/II

Completed

LY3381916

LY3300054

Solid Tumor, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Triple Negative Breast Cancer

NCT03343613

I

Terminated

KHK2455

Avelumab

Urothelial Carcinoma

NCT03915405

I

Active, not recruiting

Arginase

Prevent arginine catabolize to immunosuppressive molecules and arginine exhaustion

INCB001158

Drug: chemotherapeutic drugs

Biliary Tract Cancer, Colorectal Cancer, Endometrial Cancer, Gastroesophageal Cancer, Ovarian Cancer, Solid Tumors

NCT03314935

I/II

Active, not recruiting

Drug: Epacadostat (anti-IDO)

Drug: Pembrolizumab

Solid Tumors

NCT03361228

I/II

Terminated

Biological: Daratumumab SC

Relapsed or Refractory Multiple Myeloma

NCT03837509

I/II

Completed

AHR

Block the trp-kyn-AHR pathway

IK-175

Drug: nivolumab

Advanced Solid Tumors, Metastatic Solid Tumors, Urothelial Carcinoma

NCT04200963

I

Recruiting

Head and Neck Squamous Cell Carcinoma

NCT05472506

I

Not yet recruiting

BAY2416964

Drug: Pembrolizumab

Advanced Solid Tumors

NCT04999202

I

Recruiting

Advanced Solid Tumors

NCT04069026

I

Recruiting